untitled
|
|
- さゆり たなせ
- 7 years ago
- Views:
Transcription
1 7 ( )
2 . 1. (C.difficile associated disease CDAD) 1) CDAD CDAD Toxin CDAD 2) (1) C.difficile C.difficile (2) C.difficile (toxin A toxin B) toxin A toxin B (A+B+) toxin A toxin B (A-B+) (A-B-)A-B+ A+B (BI/NAP1/027 ) (3) CDAD 3 ( C.difficile ) () toxin A IgG CDAD IgG CDAD 3) C.difficile 20 30% CDAD
3 4) CDAD (1) 20 25% 2 3 (2) CDAD CDAD MRSA C.difficile CDAD 5) (1) CDAD 0.02% 0.05% ( ) 0.02% 0.05% 2 C.difficile
4 2. 1) (ICA ) (BCYE ) 2) ( ) - 3) - 4) ) 4
5 3. 1) gold-standard -PCR -D- 2) OKT3 Aspergillus fumigatus Aspergillus flavus Aspergillus niger 3) ( ) ( )
6 4) PCR B B B 2 PCR CT 1 2 5) HEPA LAF(laminar air flow)
7 4. 1) (Bordet-Gengou) CSM(cyclodextrin solid medium) PT 4 (PCR LAMP ) 4 2) (Bordetella pertussis) (Bordetella parapertussis) 7 10 ( 5 21 ) DPT ( ) ) ( ) 1 10 (staccato) (whoop) (reprise) 2 (whoop) 1 (CDC) ( )
8 4) (1) ( ) 7 21 ( ) 7 5) 2 ( ) (1) ( ) 1,600mg( 1,600mg 8 ) mg( 800mg 4 ) 7 ( 500mg 2 ) 5 5 7
9 6)
10 5. 1) 2) () 3) (1) ( ) (2) (3) 4) ( ) (200µg/kg 1 ) %( )
11 1 1 ( 10% (BB) ) ( ) %( ) 5) (1) ( )
12 (2) 10
13 6. 1) CJD (definite) CJD (probable) ( ) (possible) 2) (CJD) CJD
14 3) (1) CJD Web ( 20 ) ( 21 7 ) (2) 1% (3) ( ) CJD
15 IVH CJD CJD CJD CJD
16 2
1 16 2 3 4 5 6 7 6.02 6.10 6.02 6.02 8 6.03 6.02 6.10 6.03 6.02 9 6.03 6.03 6.10 6.09 6.03 6.02 6.02 6.10 6.09 6.03 6.03 10 2.02 2.41 Aspergillus niger Aspergillus brasiliensis Aspergillus niger Aspergillus
More informationMicrosoft Word - 表紙資料2-4
(1) / 130 g 25 g 520% 170 g 30 g 560% 70 mg 600 mg 11.6% 0 10.5 mg 0% (1) (2) / 50100 g 25 g 200400% 50100 g 30 g 167333% 5001000 mg 600 mg 83167% 1020 mg 10.5 mg 95190% (2) / (1) 45.6 g 30 g 152% (2)
More information/9/ ) 1) 1 2 2) 4) ) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x ) x 2 8x + 10 = 0
1. 2018/9/ ) 1) 8 9) 2) 6 14) + 14 ) 1 4 8a 8b) 2 a + b) 4) 2 : 7 = x 8) : x ) x ) + 1 2 ) + 2 6) x + 1)x + ) 15 2. 2018/9/ ) 1) 1 2 2) 4) 2 + 6 5) ) 2x + y 42x + y + 1) 4) : 6 = x 5) : x 2) x 2 15 12
More informationEPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
More informationありがとうございました
- 1 - - 2 - - 3 - - 4 - - 5 - 1 2 AB C A B C - 6 - - 7 - - 8 - 10 1 3 1 10 400 8 9-9 - 2600 1 119 26.44 63 50 15 325.37 131.99 457.36-10 - 5 977 1688 1805 200 7 80-11 - - 12 - - 13 - - 14 - 2-1 - 15 -
More informationEPSON エプソンプリンタ共通 取扱説明書 ネットワーク編
K L N K N N N N N N N N N N N N L A B C N N N A AB B C L D N N N N N L N N N A L B N N A B C N L N N N N L N A B C D N N A L N A L B C D N L N A L N B C N N D E F N K G H N A B C A L N N N N D D
More information公務員人件費のシミュレーション分析
47 50 (a) (b) (c) (7) 11 10 2018 20 2028 16 17 18 19 20 21 22 20 90.1 9.9 20 87.2 12.8 2018 10 17 6.916.0 7.87.4 40.511.6 23 0.0% 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2.0% 4.0% 6.0% 8.0%
More informationQ1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 A B (A/B) 1 1,185 17,801 6.66% 2 943 26,598 3.55% 3 3,779 112,231 3.37% 4 8,174 246,350 3.32% 5 671 22,775 2.95% 6 2,606 89,705 2.91% 7 738 25,700 2.87% 8 1,134
More information橡hashik-f.PDF
1 1 1 11 12 13 2 2 21 22 3 3 3 4 4 8 22 10 23 10 11 11 24 12 12 13 25 14 15 16 18 19 20 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 144 142 140 140 29.7 70.0 0.7 22.1 16.4 13.6 9.3 5.0 2.9 0.0
More information198
197 198 199 200 201 202 A B C D E F G H I J K L 203 204 205 A B 206 A B C D E F 207 208 209 210 211 212 213 214 215 A B 216 217 218 219 220 221 222 223 224 225 226 227 228 229 A B C D 230 231 232 233 A
More informationネットショップ・オーナー2 ユーザーマニュアル
1 1-1 1-2 1-3 1-4 1 1-5 2 2-1 A C 2-2 A 2 C D E F G H I 2-3 2-4 2 C D E E A 3 3-1 A 3 A A 3 3 3 3-2 3-3 3-4 3 C 4 4-1 A A 4 B B C D C D E F G 4 H I J K L 4-2 4 C D E B D C A C B D 4 E F B E C 4-3 4
More information1
1 2 3 4 5 (2,433 ) 4,026 2710 243.3 2728 402.6 6 402.6 402.6 243.3 7 8 20.5 11.5 1.51 0.50.5 1.5 9 10 11 12 13 100 99 4 97 14 A AB A 12 14.615/100 1.096/1000 B B 1.096/1000 300 A1.5 B1.25 24 4,182,500
More information05[ ]戸田(責)村.indd
147 2 62 4 3.2.1.16 3.2.1.17 148 63 1 3.2.1.F 3.2.1.H 3.1.1.77 1.5.13 1 3.1.1.05 2 3 4 3.2.1.20 3.2.1.22 3.2.1.24 3.2.1.D 3.2.1.E 3.2.1.18 3.2.1.19 2 149 3.2.1.23 3.2.1.G 3.1.1.77 3.2.1.16 570 565 1 2
More information広報さっぽろ 2016年8月号 厚別区
8/119/10 P 2016 8 11 12 P4 P6 P6 P7 13 P4 14 15 P8 16 P6 17 18 19 20 P4 21 P4 22 P7 23 P6 P7 24 25 26 P4 P4 P6 27 P4 P7 28 P6 29 30 P4 P5 31 P5 P6 2016 9 1 2 3 P4 4 P4 5 P5 6 7 8 P4 9 10 P4 1 b 2 b 3 b
More information<4D6963726F736F667420576F7264202D2081A193B98BE257656290EA97708CFB8DC08B4B92E88179918D8D878CFB8DC0817A816990568B4B816A81798A6D92E894C5817A2E646F63>
More information
( )
Web Web 1 3 1 21 11 22 23 24 3 2 3 4 5 1 1 11 22 9 2 3 15 11 22 2 11 21 4 5 ( ) 102 ( ) 1 ( 1 2001 Web 1 5 4 1 1 - 7 - [] - 7 10 11 12 12 1 10 1 12 - [] 1 1 2 Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 Q9 Q10 3 1 47
More information夏目小兵衛直克
39(1906)1222 14(1817) 3(1832)1514(1843) 2628 6 (1853) (1854)3727 3(1856) 1 / 13 5(1858)6(1859) 5(1853) () () () () () () 3(1867)29 504111( 2 / 13 )98 23 18 2(1869)310283 100 50() 58 226 3313200982 5033
More informationnenkin.PDF
1 31 1 WEB 10 3,544 429 13 10 22 11 7 WEB 1 2 41.0 15 80.0 20 46.7% 1000 55.8 1000 34.4 21 18.2 1000 23 25 41.0 49.2 29 90.6 42.7 33 56.4% 79.2% 67.4 51.7 37 39 83.7 1 91.0 93.6 9 2 3 1000 96.3 300 1000
More information-1-
-1- -2- -3-1 8 6% 2 4 6 8 1 48 63 43 6 55 38 78 58 2 88 67 11 22 78 1 56 22 89 47 34 36 32 38 4 34 26 7 -4- 18-5- 3 25 28 (6.%) (6.%) (.9%) 2 15 18 158 1 (3.8%) (56.4%) 5 2 137 27 8 1 68 119 26 71 28 65
More information08-02 生命の定義と遺伝.pptx
1 2 (1) (2) (3) (1) (2) DNA (3) (4) (ATP) Richard Dawkins () DNARNA () ( ) ( ) 1 2 2 1 heredity inheritance (Genetics) 1865 (1909 - - - DNA Molecular Genetics 1920 1953 ) 1. (P) (F1) (F2) 2. 1 2 3 web
More information-51-
-50- -51- 11 3 28 8 1 24 7 2 36 10 1-52- -53- 1 2-54- 6 1 2 3 4 5 6 6 1 19 5 200 300ml 20 6 400ml -55- -56- 10-57- 4 2 20-58- 2,500-59- -60- -61- 2-62- 6 3-63- 9 68 1 6-64- 3-65- 4-66- 5 6-67- -68- 1 1
More information37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate
37, 9-14, 2017 : 36 2015 8 6 cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin 20 1983 2016 3 CD 7 Clostridium difficile CD CD associated diarrhea : CDAD CD 1,2 PPI 3 1 36 33 2015 8 6 5 5
More information, 1. x 2 1 = (x 1)(x + 1) x 3 1 = (x 1)(x 2 + x + 1). a 2 b 2 = (a b)(a + b) a 3 b 3 = (a b)(a 2 + ab + b 2 ) 2 2, 2.. x a b b 2. b {( 2 a } b )2 1 =
x n 1 1.,,.,. 2..... 4 = 2 2 12 = 2 2 3 6 = 2 3 14 = 2 7 8 = 2 2 2 15 = 3 5 9 = 3 3 16 = 2 2 2 2 10 = 2 5 18 = 2 3 3 2, 3, 5, 7, 11, 13, 17, 19.,, 2,.,.,.,?.,,. 1 , 1. x 2 1 = (x 1)(x + 1) x 3 1 = (x 1)(x
More informationフィナレビ106号.indb
2009 3 30 2009 4 14 CDC 2009 4 25 WHO 2009 4 26 2009 4 28 2009 4 28 2009 4 30 2009 5 1 2009 5 8 6 2009 5 9 2009 5 23 2009 6 3 2009 6 9 2500 2009 6 12 WHO 6 2009 6 28 2009 8 9 1 1 2009 8 15 2009 8 19 2010
More informationEPSON LP-8900ユーザーズガイド
3 4 5 6 7 8 abc ade w p s 9 10 s s 11 p 12 p 13 14 p s 15 p s A B 16 w 17 C p 18 D E F 19 p w G H 20 A B 21 C s p D 22 E s p w 23 w w s 24 p w s 25 w 26 p p 27 w p s 28 w p 29 w p s 30 p s 31 A s B 32
More information12 12 10 3 17 1 1 3 17 1 4,800 8 370 2,050 17:3022:00 L.O.20:30 6,800 10 370 3 1,650 17:3024:00 L.O.23:30 1,200 3,300 8 BAR BAR B&B WEB TEL 024-984-2130 MAP TEL TEL MAP MAP TEL MAP 1 TEL
More information橡アロマセラピー症状別処方例.PDF
1 1 92 E 100ml 1 2 2 1 93 0.5m 10ml 100ml 1 2 3 2 52 0. l 2 4 3 27 3 1 1 3 3 4 5 3 2g 2 3 1 1 1 10ml 3 4 6 3 29 2 2 2 10ml 3 3 4 7 3 30 2 1 2 10ml 3 3 4 8 3 31 1 1 1 1 3 60 10 10 3 2 4 10ml A 2 3 61 20
More information2015taisetumatome.rtf
B B B( ) B3 - B3 1 3g 1/3 B 1. B1() B1() 2. B2() B2() 3. B5() B5() 4. B6() B6()( ) 5. B12() B12() 6. 1q60 160m 50m 50m 20m 8520 80 10 64 5075 30 80 B B 1 30 BB BC EPA . ?? 6 C E C 1 30 1 0.4mg4
More information合併後の交付税について
(1) (2) 1 0.9 0.7 0.5 0.3 0.1 2 3 (1) (a), 4 (b) (a), (c) (a) 0.9 0.7 0.5 0.3 0.1 (b) (d),(e) (f) (g) (h) (a) (i) (g) (h) (j) (i) 5 (2) 6 (3) (A) (B) (A)+(B) n 1,000 1,000 2,000 n+1 970 970 1,940 3.0%
More information54 144 144 144 144 144 80 152 84 122 HTML
54 144 144 144 144 144 80 152 84 122 HTML P20 P24 P28 P40 P54 P84 P122 P138 P144 P152 P220 P234 P240 P242 1 1-1 1-2 1-3 1-4 1-5 1 1-6 1 2 2-1 2-2 A C D E F 2 G H I 2-3 2-4 C D E E A 2
More informationPX-047A Series
B K L & L & A B C D E F A B A B C A B C A B A B A B C D E F G P BB H I y y & & K L L & & K L L L L & & & & L d L & & & & L L & & & L & & & & L & & & & & & & & L L L L L L & & & A B C D E F G
More information00 0 0 0 0 0 00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0.... 0........ 0 0 0 0 0 0 0 0 0 0..0..........0 0 0 0 0 0 0 0 0 0 0.... 0........ 0 0 0 0 0 0 0 0 0 0... 0...... 0... 0 0 0 0 0 0..0 0... 0 0 0 0 0.0.....0.
More information140 120 100 80 60 40 20 0 115 107 102 99 95 97 95 97 98 100 64 72 37 60 50 53 50 36 32 18 H18 H19 H20 H21 H22 H23 H24 H25 H26 H27 1 100 () 80 60 40 20 0 1 19 16 10 11 6 8 9 5 10 35 76 83 73 68 46 44 H11
More information福岡大学人文論叢47-3
679 pp. 1 680 2 681 pp. 3 682 4 683 5 684 pp. 6 685 7 686 8 687 9 688 pp. b 10 689 11 690 12 691 13 692 pp. 14 693 15 694 a b 16 695 a b 17 696 a 18 697 B 19 698 A B B B A B B A A 20 699 pp. 21 700 pp.
More information2
1 2 3 4 5 ( ) 6 7 8 "proteinaceous infectious particles" ( ) (PrP Sc ) (PrP C ) PrP C PrP Sc PrP Sc 9 10 (1) (2) 11 12 13 14 15 16 (1) (2) (3) 17 (4) (5) 18 19 20 21 22 23 24 (1) Creutzfeldt-Jakob - -.
More information(21.5%) ( %) ( %)
2018 GDP 564.3 2025 GDP 645.6 2040 GDP 790.6 39.2 (7.0%) 10.7 (1.9%) 47.8 47.4 15.3 (2.4%) (7.4%) (7.3%) 68.5 66.7 25.8 (3.3%) (8.4%) (8.7%) 49.9 62.763.1 92.594.3 (8.8%) (9.79.8%) (11.711.9%) 2018 GDP
More informationB's Recorderマニュアル_B's Recorderマニュアル
5 Part 6 - 8 9 - 0 5 A C B AB A B A B C 7-6 - 8 9-5 0 5 7 A D B C E F A B C D F E 6 9 8 0 Part - - 5 5 7 6 9-7 6 8 0 5 5-6 7 9 8 5-5 50 5 5 5 -6 5 55 5 57-7 56 59 8 7 6 58 0 8 9 6 6 7 6 5 60 7 5 6 6-8
More informationB's Recorderマニュアル
2 3 4 5 Part 1 6 1-1 8 9 1-2 10 11 12 13 A B C A C B AB A B 14 15 17 1-4 2 1 16 1-3 18 19 1-5 2 1 20 21 22 23 24 25 A B C D E F A B C D E F 26 27 28 29 30 31 Part 2 32 2-1 2-2 1 2 34 35 5 37 4 3 36 6 2-3
More information05-d m-4.03
Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 51(51) ABPA(M) 1 ABPM ITCZ 2 ABPA ITCZ 3 ABPA ABPM ABPM 52(52) THE JAPANESE JOURNAL OF ANTIBIOTICS 58 1 Feb. 9 2004 3 6 4 Feb. THE JAPANESE JOURNAL OF ANTIBIOTICS
More information日医雑誌第126巻第9号
[] HIV 4 sexually transmitted diseases 1975 WHO 12 3 2 5 3 1 1 4 3 40 1 1947 4 WHO 1975 STDsexually transmitted diseases STIsexually transmitted infection 5 STD 5 10 20 5 5 HIV STD RTIreproductive tract
More informationCandida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents
D 012 Candida albicans In Vitro Diagnostics (13)--D-Glucan Determination Reagents DATA : 1 DATA : 2 3 DATA : UNGITEC 1 1 DATA : 20pg/mL 1020pg/mL 10pg/mL (cut off 20pg/mL) 90.2%(37/41) 100%(85/85) 96.8%(122/126)
More informationuntitled
6 ( ). 1.. 1. 2. 3. 4. 5. ( ) 6. 7. 8. . 1. 1) 1 (12 3 ) 2 2) 3) ( ) ( ) 4) 2 () 2 2 3 5) ( ) R-Book ATLAS () 8 12 7 18 14 16 10 21 14 23 16 18 16 18 12 25 4 14 21 1 4 2 3 4 4 1 2 7 5 1 2 5 7 9 1 1 5 5
More information% 89 15% 75 29% ABAB
2016 4 2020 2030 2040 2050 142 303 1 1 2 30 40 50 60 90 1% 89 15% 75 29% 61 2030 2040 2050 2020 3040 2020 2020 2030 2030 2040 2040 2016 1 ABAB 2050 2050 1 2 1 2 90% 1% 15% 29% 89 75 61 47% 43 65% 25 30
More informationuntitled
117 118 119 120 121 ab ab 1 122 123 124 125 / a 124 128.9 125.2 128.9 b 113 117.9 114.2 117.9 a b 97 101.9 98.2 101.9 99 103.9 100.2 103.9 62 66.9 63.2 66.9 57 61.9 58.2 61.9 102 106.9 103.2 106.9 102
More informationuntitled
7/67/1073,42911 15,020158,393 7/127/184,6674,913 2927 71.3 894 21.8 287 7.0 n=4108) 132 3.2 62 1.5 934 22.7 786 19.1 629 15.3 801 19.5 407 9.9 357 8.7 (n=4108) 35 35 30 25 20 15 10 153 3.7 1 0.02 23 0.6
More information報告書
8 8 2 8 3 8 4 6 8 3 152 2 34849 4 38pt 32pt29pt 1 2 12 2 1 2 3 2 173 2 1 8 7 Q1 Q1 8 9 Q2 Q2 8 10 Q3 Q32 21 8 11 Q4 Q42 ( )) 21 8 12 Q5 Q52 ( )) 21 8 13 Q6 Q6 ( )) 8 14 Q7 Q7 ( )) 8 15 Q8 Q8 ( )) 8 16
More informationuntitled
16 4 1 17 1 50 -1- -2- -3- -4- -5- -6- -7- 1 2-8- -9- -10- -11- Web -12- (1) (2)(1) (3) (4) (1)()(2) (3)(4) -13- -14- -15- -16- -17- -18- -19- -20- -21- -22- -23- (2)(1) (3) -24- -25- -26- -27- -28- -29-
More informationA B ( +A+B) H g H27 H28 H29 H30 189, , , , , , , , ,
04 01 03 01 001505000 30 7 1 30 10 A B (+A+B) H36 11 g 851 30.1 H27 H28 H29 H30 189,405 160,401 149,683 138,928 165,746 133,618 125,755 107,100 103,700 96,700 96,700 272,846 237,318 222,455 235,628 H27
More informationBIT -2-
2004.3.31 10 11 12-1- BIT -2- -3-256 258 932 524 585 -4- -5- A B A B AB A B A B C AB A B AB AB AB AB -6- -7- A B -8- -9- -10- mm -11- fax -12- -13- -14- -15- s58.10.1 1255 4.2 30.10-16- -17- -18- -19-6.12.10
More information肝臓病教室201207v2配布用.pptx
24 7 28 5 C C C C 11 1 vs 2 vs 1 0 1 600-1000mg 3-5/ 24,48 2448 12 1 1500-2250mg 6-9/ () 1 600-1000mg 3-5/ 0 24 88.1% 0 20 40 60 80 100 C ALT, GPT 30 34.4% ALT, GPT 0 20 40 60 80 100 2 , 2 3 1 1-100% 0
More informationWeb Java. 20073 20073 Happy Choice! (2007120073) 2,129 2,288 97 110 43 58 96 111 OK PCR CADSEPG Temp To Perm 2,288 2,454 111 110 58 118 120 60 47 4 24 14 7.5 7.5 27.2 2,4541657.2 11887.2 4.8
More information14 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 20 0 0 0 0 0 0 0 0 0 0 0 0 21 0 0 0 0 0 0 0 0 0 0 0 0 22 0 0 0 0 0 0 0 0 0 0 0 0 23 0 0 0 0 0 0 0 0 0 0 0 0 24 0 0 0 0 0 0 0 0 0 0 0 0 25 0 0 0 0 0 0 0 0 0
More informationAJISAI10-1.PDF
Vol.10,No.1,2001 Jan.2001 Vol.10 No.1 *1 50 10 30 DDT 1980 200 Sarcoptes Scabiei var 0.330.35mm 0.25 Hominis 0.35mm 2/3 1mm 4 1 Vol.10,No1,2001 4 1040 2mm 23 20%KOH 1 13 34 6 2 1417 8 4 1014 45 1025 10
More information8 8 0
,07,,08, 8 8 0 7 8 7 8 0 0 km 7 80. 78. 00 0 8 70 8 0 8 0 8 7 8 0 0 7 0 0 7 8 0 00 0 0 7 8 7 0 0 8 0 8 7 7 7 0 j 8 80 j 7 8 8 0 0 0 8 8 8 7 0 7 7 0 8 7 7 8 7 7 80 77 7 0 0 0 7 7 0 0 0 7 0 7 8 0 8 8 7
More information(1)
~ ~ NO YES ~ ( NO YES ) YES NO NO YES ~ ( NO YES ) YES NO 1 1 NO 2 NO 2YES YES 1 (1) 25 26 2 3 () () () () 4 () () 5 6 () 7 () 8 9 1-3-1 10 3 11 12 ~1. (1) () () (2) (3) () (4) () () (5) (6) (7) (1) (2)
More information1.8.2 Page MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) / Candida glabrata (25) 0.25 / 0.5 Candida guilliermondii a) (2)
1.8.2 Page1 1.8.2 96% 2002 40 B 1 123 (1) in vitro 1) in vitro C. glabrata C. krusei 1 2 19951997 3 1999 2002 MIC MIC 2 1.8.2 Page2 1 19951997 MIC () MIC 50 / MIC 90 µg/ml Candida albicans (54) 0.016 /
More information第Ⅰ章
4 11 () () () () () () () () () 19 () () () () () () () () () 28 () () 30 32 34 36 37-1 - -2 - () -3 - SPSS () ()() () () () -4 - N N N -5 - () A AB B O () A AB B O N N -6 - -7 - () N= -8 - () () () -9
More informationEP760取扱説明書
D D D # % ' ) * +, B - B / 1 Q&A B 2 B 5 B 6 Q & A 7 8 $ % & ' B B B ( B B B B B B B B B B B ) B B B A # $ A B B * 1 2 # $ % # B B % $ # $ % + B B 1 B 2 B B B B B B B B B B , B B B - 1 3 2 2 B B B B B
More informationŁ½’¬24flNfix+3mm-‡½‡¹724
571 0.0 31,583 2.0 139,335 8.9 310,727 19.7 1,576,352 100.0 820 0.1 160,247 10.2 38,5012.4 5,7830.4 9,5020.6 41,7592.7 77,8174.9 46,425 2.9 381,410 24.2 1,576,352 100.0 219,332 13.9 132,444 8.4 173,450
More information4 小川/小川
B p p B pp M p T p M p Tp T pt T p T p T p p Tp T T p T p T pt p Tp p p p p p p p p T p p T T M M p p p p p p T p p p T T p T B T T p T T p T p T T T p T p p T p Tp T p p Tp T p T Tp T T p T p T p T p
More informationCT_08-01.ai
2009-12 CT55DD 80,000 CTF55B 8,000 CTF55D 3,200 41m 2 BIO HEPA ECO 5 21 20m 2 1210 4.3 1,542 http://www.kuusei.jp/ https://ssl.mhiair.co.jp/app/ contact/?form_number=3 https://ssl.mhiair.co.jp/shop/
More information2
2 3 Page 4 5 6 A-1B-1 C0 D0 E0 F0 G0 A0 B0 C1 D1 E1 F1 G1 A1 B1 C2 D2 E2 F2 G2 A2 B2 C3 D3 E3 7 F3 G3 A3 B3 C4 D4 E4 F4 G4 A4 B4 C5 D5 E5 F5 G5 A5 B5 C6 D6 E6 F6 G6 A6 B6 C7 8 Page 9 1 2 3 1 2 10 1 11
More information060407人材派遣業界における適正な健康保険年金制度の適用.doc
1 I.... 3 1.... 3 (1)... 3 (2)... 4 (3)...11 2....13 (1)...13 (2)...13 3....14...16 1....16 2....24...25 1....25 2....25 3....26 4....26 5....27 (1)...27 (2)...28 (3)...28 6....29 17 2 3 I. 1. (1) 1986
More information13,825,228 3,707,995 26.8 4.9 25 3 8 9 1 50,000 0.29 1.59 70,000 0.29 1.74 12,500 0.39 1.69 12,500 0.55 10,000 20,000 0.13 1.58 30,000 0.00 1.26 5,000 0.13 1.58 25,000 40,000 0.13 1.58 50,000 0.00 1.26
More information12„”‡Pfiú“ƒ-PDFŠp
5 Q Q Q Q ggg g f bbb -b b g b g g g a b f g r t y - 7 g bb f 6 E D f f f 2 2 2 2 2 f g f 2 f 2 f 2 g a g a b f a f g a a a - a f b a f b b b b bb bb E E E R Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q Q
More information